| INTRODUCTION
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by inflammation restricted to the large bowel mucosa. Up to one-quarter of patients with UC will eventually undergo total proctocolectomy, [1] [2] [3] [4] [5] and about 10% of patients will undergo surgery within 5 years of diagnosis, even in the biological era. 6 The most common indications for total proctocolectomy in UC are chronic active disease despite anti-inflammatory medications, or steroiddependent disease, commonly designated as refractory inflammation.
In addition, 10%-31% of patients are operated for non-refractory indications, among them dysplasia, neoplasia, or strictures. [7] [8] [9] Last, some patients are still being operated for an emergency indication not responding to rescue medications, such as acute severe colitis. 10 The surgical reconstruction of choice after total proctocolectomy is the creation of an ileal pouch-anal anastomosis (IPAA) reservoir (pouch surgery). Since UC is primarily restricted to the large bowel, it was expected that pouch surgery will enable eradication of diseased mucosa and a cure for UC. However, following the surgery, up to 60% of patients will develop inflammation of the pouch ("pouchitis"), and up to 30% may develop the more complicated phenotypes of chronic pouchitis (CP) or Crohn's-like disease of the pouch (CLDP). [11] [12] [13] [14] [15] [16] [17] [18] These conditions negatively impact patients' quality of life and often require long-term medical therapy, mostly difficult and empirical. ANCA serology, arthropathy, smoking and primary sclerosing cholangitis). 7, 13, 22, [24] [25] [26] [27] [28] [29] [30] [31] [32] Finally, a NOD2 gene variant (NOD2insC rs2066847) was found to be associated with the development of pouchitis. 33 However, this variant only exists in about 5% of patients who developed pouchitis after IPAA and in even fewer patients who did not, and can therefore not serve as a useful predictor.
In this study, we aimed to identify predictors for pouch outcome among patients with UC who underwent pouch surgery. To this end, we analysed clinical and genetic markers of a large cohort that underwent a long-term prospective follow-up.
2 | ME TH ODS were considered statistically significant.
The study was approved by the local Institutional Review Board (IRB), number 0467-10, and by the Israeli National IRB Committee, number 0587-10, and all participants provided their written informed consent.
| RESULTS
At the end of 2014, a total of 347 patients registered at the comprehensive pouch clinic database were screened for eligibility for this retrospective cohort study. Eighty-one patients were excluded as being operated for either a non-UC indication, with a non-J pouch, missing data or lack of sufficient follow-up. In addition, we excluded 13 patients with a diagnosis of UC who underwent a total proctocolectomy and IPAA with a construction of a J-pouch: three patients -urgently operated for either acute severe colitis or toxic megacolon, three patients-with early post-operative complications either leakage, early obstruction or pelvic sepsis within the first 30 days after surgery, four patients with isolated cuffitis, and three patients with an equivocal pouch outcome.
Overall there were 253 patients included in the study. Group distribution of the entire cohort is shown in 
| Prediction of long-term pouch outcome
To assess predictors for a non-favourable outcome (pouchitis), we further analysed the risk for disease progression by a Cox regression hazard model and included all the statistically significant clinical risk factors in the univariate analysis (Table 1) , as well as other potential long-term risk factors for pouchitis (ie, gender and family history of IBD). In agreement with the survival analysis, the model revealed that a refractory indication for surgery, adjusted for gender, age at IBD diagnosis, age at pouch surgery, and family history of IBD, conferred a 3.43-fold risk for pouchitis (95% CI 1.43-8.21, Table 3 ).
Indeed, separating the pouchitis patients into groups with CP or CLDP revealed that a refractory indication for surgery was a risk factor in both groups. However, the HR was 2.4 in the CP group (P=.03) compared to 14.0 in the CLDP group (P=.01). Specifically, the only significant differences between patients with a normal pouch and RAP were the longer duration between UC diagnosis and pouch surgery and the longer follow-up, both unsurprisingly resembling the pouchitis group. Overall, after 25 years since pouch surgery/ileostomy closure, most patients will develop pouchitis: 86% of the cohort developed some form of pouchitis and only 14% maintained sustained normal pouch.
| DISCUSSION
Another important finding in this study was a favourable outcome of sustained normal pouch being associated with older age at UC diagnosis, older age at pouch surgery, and longer duration between UC diagnosis and surgery. These differences most likely represent a subgroup of patients with a less aggressive inflammatory Our results are consistent with a previous report from our group in demonstrating the impact of shorter pre-surgical disease duration and longer follow-up after surgery on the progression towards pouchitis. 7 In this study, we added an important aspect, that is, the impact of pre-surgical inflammatory burden. We also showed, for the first time, that the overall long-term prognosis of the surgery is discouraging, Dharmaraj et al. 25 reported a small paediatric UC cohort and demonstrated a higher Pediatric UC Activity Index (PUCAI) score at the time of diagnosis was a risk factor for developing pouchitis, supporting our current findings. Other reports suggested various factors as predictive of pouchitis, including PSC which may reflect additional, remote inflammation. The finding that disease severity prior to surgery is associated with pouch outcome may reflect the fact that pathological changes exist in IBD patients (both CD and UC) even in areas that are grossly normal, 37, 38 and that such changes may be associated with disease severity and not exist among normal controls. 39 While our findings provide a step towards tailored strategies, the data clearly demonstrate that the long-term pouch outcome is poor even for those with no obvious risk factors. Therefore, the ultimate goal for patients with complicated UC should be not merely better pre-surgical patient selection but also the development of better therapies that will prevent the need for surgery.
The main strengths of this study are that it is a large cohort study that addresses a well-defined cohort of patients. It was conducted in a single large tertiary centre that coordinates and follows the majority of pouch patients nationwide. The stringent definitions of long-term outcome, and the exclusion of all groups with confounding characteristics that may impact pouch outcome or else have an equivocal outcome (post-surgical complications and/or RAP)
are an additional strength.
The study could have had more merit if biological materials, including serologic markers, microbiome and molecular phenotypic data, both before and after surgery, would be available for a larger number of patients within our cohort. In addition, to study the impact of the a-priori inflammation of patients with UC on long-term pouch outcome, it would have been valuable to compare proctitis vs pancolitis or mild vs severe disease. However, these comparisons are obviously impossible since patients with proctitis usually do not require total proctocolectomy (about 7% of our cohort had proctitis pre-pouch surgery). Last, all non-refractory patients had either cancerous or pre-cancerous lesions, a neoplastic process that in and of itself may have a distinct impact on the long-term outcome of the pouch. Furthermore, the presence of a neoplastic lesion did not completely abort the development of pouchitis, thus potentially representing a confounder.
To summarize, our findings demonstrate that most pouches of patients with UC will become inflamed and patients will develop pouchitis over time. Patients with an increased inflammatory burden at the time of surgery are more likely to develop pouchitis. Moreover, this wearing down of the pouch will happen sooner in patients with refractory disease compared with patients who did not have a refractory disease at the time of surgery. The results suggest that pouch surgery does not impact the fundamental inflammatory process or the natural history of the background disease, and that the processes determining UC severity are probably similar to those causing pouchitis. While understanding these processes may assist in directing clinicians with decision-making in different situations, it is still impossible to predict outcome on a case-by-case basis.
Advanced characterisation of patients with UC based on combined clinical, microbial, genetic and molecular (expression) variables, both at the time of surgery and after surgery, is needed to develop an optimal predictive tool. Such data may provide insight into the immunopathology of UC and pouchitis, and potentially on that of CD, and will provide clinicians with the optimal therapeutic strategies and, hopefully, even guidelines for prevention.
